Use of tactivin and imunofan for the treatment of patients with endometrial carcinoma
Venediktova MG · 2001 · Eksperimental'naia i klinicheskaia farmakologiia 2001
Reported findings and study design
Both adjunctive Tactivin and Imunofan were reported to reduce radiation complications and improve immune measures. The authors described Imunofan as somewhat more effective, without numerical rates.
Patients receiving complex treatment for endometrial adenocarcinoma; sample sizes not supplied in the indexed abstract.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Radiation complications and immune measures | Improvement reported with both agents; Imunofan described as more effective; numerical rates absent |
No group sizes, allocation details, complication counts or cancer-survival endpoints are supplied. This does not establish either preparation as an anticancer therapy.
Source for the extracted data ↗ · Checked 2026-11-01
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- No group sizes, allocation details, complication counts or cancer-survival endpoints are supplied. This does not establish either preparation as an anticancer therapy.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Indexed abstract checked
Source access and review scope
Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Recorded source-check date: 2026-11-01. This date does not imply a completed systematic review.
Source type: Journal publication
Citation and original source
Original source: Venediktova MG. Use of tactivin and imunofan for the treatment of patients with endometrial carcinoma Eksperimental'naia i klinicheskaia farmakologiia 2001 2001.
Molekul research summary: https://molekul.io/research/thin-11764501. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Tactivin
Thymus-derived polypeptide preparation studied as an immune adjunct and in animal learning models. Clinical findings include a reported infection reduction in leukemia and a neutral melanoma comparison.
Imunofan
A synthetic RDKVYR hexapeptide with cell, animal and human wound-related research. Historical Thymohexin names have conflicting sequence order.